Cook IVC Filter Study

Overview

This prospective, multicenter, double-arm clinical study further evaluated the safety and effectiveness of Cook's commercially available inferior vena cava (IVC) filters (specifically, the Günther Tulip® Vena Cava Filter and Cook Celect® Vena Cava Filters) in patients in need of temporary or permanent IVC filter placement for the prevention of pulmonary embolism (PE).

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Non-Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: December 18, 2018

Interventions

  • Device: Günther Tulip® Vena Cava Filter
    • Temporary or permanent filter placement for the prevention of pulmonary embolism
  • Device: Cook Celect® Vena Cava Filters
    • Temporary or permanent filter placement for the prevention of pulmonary embolism

Arms, Groups and Cohorts

  • Experimental: Günther Tulip® Vena Cava Filter
    • Günther Tulip® Vena Cava Filter
  • Experimental: Cook Celect® Vena Cava Filters
    • Cook Celect® Vena Cava Filters

Clinical Trial Outcome Measures

Primary Measures

  • The Number of Participants With Technical Placement Success and With 12-month Freedom From New Symptomatic Pulmonary Embolism (PE) While a Filter is Indwelling.
    • Time Frame: 12 months
    • The protocol defined technical placement success as: deployment of filter in a location suitable to provide sufficient mechanical protection against PE with no filter deformation, fracture, premature release, or clinical migration (caudal or cranial movement of a filter resulting in a surgical or endovascular intervention).
  • The Rate of 12-month Freedom From Major Adverse Events (MAEs)
    • Time Frame: 12 months
    • MAEs were defined as clinical perforation, clinical migration, clinical fracture, embolization of the filter or filter fragments to the heart or lungs, IVC thrombotic occlusion, new symptomatic DVT while the filter is indwelling, access site complications with clinical sequelae, and procedure-/device-related death. Clinical perforation – Protrusion of filter legs through the wall of the IVC causing hemorrhage or hematoma or touching, impressing, or perforating another organ. Documented using CT. Clinical migration – Caudal or cranial movement of a filter resulting in surgical or endovascular intervention. Clinical fracture – A loss of structural integrity (breakage or separation) of the filter identified by imaging and associated with clinical sequelae and/or requiring intervention.
  • Supplemental Analysis to the Safety Endpoint: The Number of Participants With 12-month Freedom From Major Adverse Events (MAEs).
    • Time Frame: 12 months
    • MAEs were defined as clinical perforation, clinical migration, clinical fracture, embolization of the filter or filter fragments to the heart or lungs, IVC thrombotic occlusion, new symptomatic DVT while the filter is indwelling, access site complications with clinical sequelae, and procedure-/device-related death. A filter retrieval is considered a successful safety result through 12 months, regardless of when the retrieval occurred.

Secondary Measures

  • Rate of Technical Placement Success and 12-month Freedom From New Symptomatic PE While Filter is Indwelling
    • Time Frame: 12 months
    • Rate of technical placement success and 12-month freedom from new symptomatic PE while a filter is indwelling for the combined patient population (i.e., the Celect and Günther Tulip strata). The protocol defined technical placement success as: deployment of filter in a location suitable to provide sufficient mechanical protection against PE with no filter deformation, fracture, premature release, or clinical migration (caudal or cranial movement of a filter resulting in a surgical or endovascular intervention).
  • Rate of 12-month Freedom From Major Adverse Events for the Combined Patient Population (i.e., the Celect and Günther Tulip Strata)
    • Time Frame: 12 months
    • MAEs were defined as clinical perforation, clinical migration, clinical fracture, embolization of the filter or filter fragments to the heart or lungs, IVC thrombotic occlusion, new symptomatic DVT while the filter is indwelling, access site complications with clinical sequelae, and procedure-/device-related death. Clinical perforation – Protrusion of filter legs through the wall of the IVC causing hemorrhage or hematoma or touching, impressing, or perforating another organ. Documented using CT. Clinical migration – Caudal or cranial movement of a filter resulting in surgical or endovascular intervention. Clinical fracture – A loss of structural integrity (breakage or separation) of the filter identified by imaging and associated with clinical sequelae and/or requiring intervention.
  • Number of Participants With Freedom From Grade 2 or Grade 3 Filter Leg Interaction With IVC, Filter Migration, Filter Fracture, and Filter Embolization at 12-month.
    • Time Frame: 12 months
    • Filter interaction with IVC is defined as : Grade 2: Filter strut is entirely outside of the IVC lumen and within the retroperitoneum as evidenced by a “halo” of retroperitoneal fat around axially viewed strut. Grade 3: Filter strut is touching, impressing, or perforating another organ (e.g., liver, bowel, aorta, psoas muscle, vertebral body, lymph nodes). Filter migration : Change in filter position compared to its deployed position (cranial or caudal). Filter fracture : Any loss of structural integrity (breakage or separation) of the filter identified by imaging or autopsy. Documented by imaging or at autopsy. Filter embolization : Post-placement movement of the filter or its components to a distant anatomic site completely out of the target zone (i.e., heart/lungs). Documented by imaging or autopsy.

Participating in This Clinical Trial

Inclusion Criteria

  • Requires temporary or permanent IVC filter placement for the prevention of PE Exclusion Criteria:

  • Less than 18 years of age – Known hypersensitivity or contraindication to contrast medium that cannot be adequately premedicated – Known allergy or sensitivity to cobalt, chromium, or nickel – Pregnant or planning to become pregnant in the next 12 months – Patient refuses blood transfusions – At risk of septic embolism – Medical condition or disorder that would limit life expectancy to less than 12 months or that may cause noncompliance with the protocol or confound the data analysis – Existing IVC filter – Duplicate IVC – Anatomy that would prevent safe filter placement (e.g., condition of access vessels) – IVC diameter > 30 mm or < 15 mm

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Cook Research Incorporated
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • H. Bob Smouse, MD, Principal Investigator, OSF St. Francis/Peoria Radiology Research and Education Foundation
    • Robert Feezor, MD, Principal Investigator, University of Florida Health-Shands

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.